Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
A new study analyzed tumor biopsies from patients with newly-diagnosed germinal center B cell lymphoma and found that CREBBP mutations were associated with lower disease-free survival rates. The researchers identified CLMA as a practical tool to translate experimental findings into clinical applications.
Scientists have identified a potential therapy to reduce the side effects of cisplatin chemotherapy, which can cause kidney toxicity and neuropathic pain. Istradefylline, an approved Parkinson's disease drug, has been found to mitigate these harmful effects while preserving cisplatin's anti-tumor properties.
Neuroblastoma tumour cells adapt to mimic embryonic cells, making them resistant to chemotherapy. This understanding can lead to targeted treatments that better reach the entire tumour and avoid resistance development.
Researchers from the University of Zurich have discovered why a stem cell transplant is effective in treating multiple sclerosis. The study found that memory T cells reappear immediately after the transplant and do not trigger an autoimmune reaction due to pre-damage caused by chemotherapy. This knowledge enables the body to gradually ...
The West Texas Pharmacology Core laboratory at TTUHSC will focus on two primary areas: drug development and pediatric cancer. The core aims to address obstacles in drug development, including limited pharmacology expertise for small biotech companies and low profitability for pediatric cancer drugs.
A new study published in JNCCN found significant disparities in ovarian cancer treatment based on patient race, ability to pay, and healthcare access. Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment compared to White patients.
A study using mRNA and miRNA expression profiles identified molecular signatures that can differentiate muscle invasive bladder cancer patients who respond to neoadjuvant chemotherapy from those who do not. The research found distinct gene pathways and subtypes associated with response, which may lead to more effective treatment delivery.
Research suggests that antibiotics used in ovarian cancer treatment can accelerate cancer progression and lower survival rates. Reintroducing healthy gut bacteria may slow down cancer growth and restore sensitivity to chemotherapy.
A combination of pembrolizumab and nanoparticle-bound paclitaxel has shown a high response rate of 50% in patients with platinum-refractory or ineligible urothelial cancers. The treatment has also been associated with improved median duration of response and overall survival time, providing an urgently needed new treatment option.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers have designed DNA-based transporters that can deliver precise concentrations of drugs, potentially improving cancer treatment. These nanotransporters can also be programmed to prolong the effect of a drug and minimize its dosage, reducing side effects.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
Researchers mapped the detailed neural pathway of defensive responses from the gut to the brain in mice after detecting germs. The study could lead to better anti-nausea medications for cancer patients undergoing chemotherapy.
Two new discoveries led by Cedars-Sinai Cancer investigators improve understanding of ovarian cancer's development and suggest personalized therapeutic approaches. They identified four new genetic regions linked to increased ovarian cancer risk and found that some tumors may develop resistance to chemotherapy from an early stage.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
A study published in JACC: CardioOncology found that exercise during chemotherapy improves long-term cardiorespiratory fitness and alleviates adverse effects of cancer treatment. After treatment, an exercise program can recover lost function. The optimal timing of exercise intervention is during chemotherapy.
A novel polysorbate-based formulation enhances carboplatin's therapeutic response in lymph nodes, amplifying antitumor effects and increasing drug penetration.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Scientists from NTU Singapore have discovered that telomeres are stacked in columns like a spring, leaving DNA exposed to damage. This finding could improve understanding of how humans age and develop cancer, with potential treatments for diseases caused by dysfunctional telomeres.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Researchers found that using the Bazett formula to assess heartbeat rhythms can lead to inaccurate chemotherapy modifications, potentially affecting patient care. Standardizing formulas with electrocardiograms can reduce this risk and improve treatment outcomes.
Cancer cells become resistant to chemotherapies by slowing down DNA replication forks, allowing them to avoid collisions with chemotherapy drugs. A kinase called DNA-PKcs acts as a sensor when a fork is stressed and promotes slowing of the fork and chemo-resistance.
A recent study published in the Journal of the National Cancer Institute found that cancer and chemotherapy do not appear to increase the risk of stillbirth among adolescent and young adult women who later become pregnant. The study included data from 11,696 deliveries to over 8,400 women diagnosed with cancer between 1995 and 2015.
Researchers found that inhibiting GABA A receptors protects intestinal stem cells from chemotherapy and radiotherapy-induced damage, reducing DNA damage and increasing survival. Flumazenil, an FDA-approved anti-sedative, shows promise in protecting the intestine from these toxic effects.
Researchers at Tohoku University have developed a novel cancer therapy combining lymphatic drug delivery with total-body irradiation, showing superior antitumor effects in early stage lymph node metastasis. The treatment enhances systemic tumor immune responses and alters the tumor microenvironment.
Scientists discover that methotrexate causes oxidative damage to the cerebrospinal fluid and choroid plexus, leading to cognitive impairment. Adding antioxidants to the CSF may protect against this damage, offering a potential treatment for 'chemo brain'. Researchers are exploring other chemotherapy drugs and testing antioxidant treatm...
Researchers found that a specific sequence of drugs can reduce overall costs and improve the value of care for patients with metastatic breast cancer, while minimizing side effects. The study's results suggest that treatment sequencing approaches that minimize costs early may improve the value of care.
A study found that resiliency and family support play a crucial role in helping Hispanic breast cancer survivors manage lymphedema. Adaptations such as modifying work tasks and seeking support from family members enable survivors to maintain their quality of life.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.
A Saint Louis University researcher has identified a potential treatment for 'chemo-brain', a debilitating side effect of chemotherapy that affects patients' quality of life. The treatment targets the molecular events underlying this deficit and repurposes an already-approved FDA drug to reduce cognitive impairment.
Researchers have genetically engineered yeast to produce vindoline and catharanthine, the precursors to vinblastine, a widely used anti-cancer drug. This breakthrough may lead to new sources of these compounds and reduce dependence on plant farming and logistics challenges.
Researchers discovered that combining a new target with an old chemotherapy drug can reduce resistance and potentially improve treatment outcomes for small cell lung cancer. The study used mouse models to show that inhibiting a protein called SMYD3, along with cyclophosphamide, stopped tumors in their tracks.
Recent studies in Journal of Pharmaceutical Analysis highlight innovative nanosensors for efficient biomolecular detection, including rutin, paracetamol, and hypochlorite. These advancements enable high sensitivity and reliability in clinical samples, paving the way for improved patient care.
Researchers identified five new hepatoblastoma tumor signatures that could help predict responses to chemotherapy treatments. The study used single-cell transcriptomic techniques to analyze tumors from infants and children, providing a window into normal development and cancer.
A pilot study from UCLA researchers found that neurofeedback training significantly normalized brain wave frequencies and improved cognitive function in cancer patients with chemo brain. The study's results support further research into the effectiveness of neurofeedback as a treatment approach.
A Swedish study of 1,275 women with breast cancer found no increased risk of disease recurrence or death after fertility preservation procedures. The research provides new hope for women who want to preserve their fertility after cancer treatment.
Scientists have identified a critical source of essential molecules that enables the intestine's self-renewal and regeneration after injury. The study reveals that lymphatic endothelial cells play a key role in maintaining stem cell activity and tissues in the intestine.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.
A new advanced MRI technique has enabled clinicians to measure the effectiveness of chemotherapy in patients with stiff heart syndrome, improving their prognosis. By accurately measuring amyloid protein deposits in the heart, doctors can better guide treatment strategies and improve patient outcomes.
A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.
A combination of gemcitabine and docetaxel shows excellent outcomes in patients with high-risk non-muscle-invasive bladder cancer. The 'Gem/Doce' therapy provides a safe and effective alternative to BCG treatment, resulting in high response rates and good tolerability.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
A study by Johns Hopkins Medicine researchers found that more than 85% of tested CBD products contained inaccurate labeling, including misstated CBD amounts and presence of THC. The study also revealed that some products made unapproved therapeutic claims, highlighting the need for better regulatory oversight.
Researchers at Massachusetts General Hospital found that paclitaxel improves clinical outcomes and is cost-effective compared to commonly used treatments in Kenya. Using paclitaxel instead of bleomycin-vincristine could save 6,400 years-of-life and reduce healthcare expenditures by $3.7 million over five years.
Researchers from Mayo Clinic Comprehensive Cancer Center found that adding brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma. The study showed that the drug has a positive impact on overall survival, regardless of other treatments administered later in the course of care.
Combination chemotherapy with FOLFIRINOX before surgery increased survival in patients with borderline resectable pancreatic cancer, outperforming FOLFIRINOX plus radiotherapy. The study demonstrated the effectiveness of neoadjuvant chemotherapy in improving outcomes for these patients.
A team of researchers developed a nanoparticle probe that can detect an indicator of heart damage from chemotherapy. Experiments revealed that intermittent fasting before chemotherapy can prevent this damage and preserve cardiac function.
Researchers have discovered eight potential leukemia-killing compounds that target mitochondria, inducing mitophagy to weaken cancer cells. The compounds showed significant synergy with existing chemotherapy drugs, offering a deadly one-two punch against leukemia.
Researchers found that tumour stem cells with Mex3a protein activity remain in a latent state, conferring resistance to chemotherapy. After treatment, these cells are reactivated, leading to cancer relapse. Removing the Mex3a gene makes colorectal cancer cells highly sensitive to chemotherapy.
Researchers at LSU Health Sciences Center have discovered a novel combination therapy that effectively treats chemo-resistant triple-negative breast cancer. The treatment combines two existing FDA-approved drugs, ceritinib and enzalutamide, to target the growth of cancer cells, showing promise for improving treatment outcomes.